SHENZHEN, China, April 9, 2024 /PRNewswire/ — nubia, a leading global smartphone manufacturer and a pioneer in innovative smartphone technology, proudly announces the launch of its groundbreaking flagship foldable smartphone, the nubia Flip 5G. Tailored specifically for the younger generation, the nubia Flip 5G fuses together cutting-edge design and powerful functionality, posed to redefine the […]
Overcoming limitations of existing LiDAR with Shortwave Infrared Rays…Detection range tripled Various line-ups tailored to customers…Secured differentiated capacity by acquiring Argo patents “Aiming to become No.1 in sensing solution for ADAS based on top-tier DNA in optics” SEOUL, South Korea, April 9, 2024 /PRNewswire/ — LG Innotek rolled up its sleeves to aim for the ADAS (Advanced […]
GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced positive interim results from the ongoing Phase 3 clinical trial (the “Phase […]
With a consolidated sales figure of US$ 732.9 million, an increase of 40.2% compared to the previous year… Annual EBITDA up by 15.9% to US$ 61.93 million Last year’s calculation included the “one-time cost” of stock rewards paid out earlier this year… “Seeking revenue generation through cost-effective growth initiatives.” SEOUL, South Korea, April 9, 2024 […]
ABU DHABI, UAE, April 9, 2024 /PRNewswire/ — Marking a milestone in the technology sector of Abu Dhabi, a visionary team has launched the Venom Blockchain, a high-caliber project that has swiftly achieved a market cap surpassing $5.2 billion, with exchange volumes toppling $200 million on leading platforms. This remarkable feat underscores Abu Dhabi’s emerging […]
BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ — Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research […]
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at the 2024 American Association for Cancer Research (AACR) Annual Meeting. GFH547 is developed with […]
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentation of the 2024 American Association for Cancer Research (AACR) Annual Meeting. GFH375 (VS-7375) is […]